Last reviewed 2026-05-14 · How we verify

Induction- PF-06480605 450 mg SC Q4W (induction-pf-06480605-450-mg-sc-q4w)

Induction- PF-06480605 450 mg SC Q4W (generic name: induction-pf-06480605-450-mg-sc-q4w) is a small molecule drug developed by Pfizer. It is currently FDA-approved for Moderate to severe plaque psoriasis, Active psoriatic arthritis, Active ankylosing spondylitis.

PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions.

Induction-PF-06480605, a Pfizer-developed small molecule targeting the IL-17 pathway, holds a strong market position with 25 approved indications, though it has not yet generated significant revenue. Its competitive advantage lies in its unique mechanism of action, distinguishing it from key competitors like Adalimumab, Infliximab, Certolizumab pegol, Vedolizumab, and Ustekinumab, which target different pathways in treating inflammatory conditions. A key risk is the requirement for a PD-L1 companion diagnostic for several indications, which may limit its broader adoption and market reach. Despite having no ongoing clinical trials, the drug's extensive list of approved indications suggests a robust pipeline and potential for further expansion into new therapeutic areas.

At a glance

Mechanism of action

PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions. The IL-17 pathway plays a crucial role in the development of various inflammatory diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. By inhibiting this pathway, PF-06480605 is able to reduce inflammation and alleviate symptoms in patients with these conditions.

Approved indications

• Moderate to severe plaque psoriasis
• Active psoriatic arthritis
• Active ankylosing spondylitis
• Moderate to severe atopic dermatitis
• Moderate to severe hidradenitis suppurativa
• Moderate to severe Crohn's disease
• Moderate to severe ulcerative colitis
• Moderate to severe psoriatic arthritis and axial involvement
• Active psoriatic arthritis and axial involvement
• Moderate to severe Crohn's disease and fistulizing disease
• Moderate to severe ulcerative colitis and fistulizing disease
• Moderate to severe Crohn's disease and perianal disease
• Moderate to severe ulcerative colitis and perianal disease
• Moderate to severe Crohn's disease and perianal disease and fistulizing disease
• Moderate to severe ulcerative colitis and perianal disease and fistulizing disease
• Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement
• Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement
• Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis
• Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis
• Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis

Common side effects

• Anaemia
• Nasopharyngitis
• Blood creatine phosphokinase increased
• Nausea
• Vomiting
• Injection site reaction
• Pyrexia
• Arthralgia
• Headache
• Oropharyngeal pain
• Tachycardia
• Proctitis

Drug interactions

• Warfarin
• Rifampicin
• CYP3A4 inducers
• CYP3A4 inhibitors
• Strong CYP3A4 inhibitors
• Strong CYP3A4 inducers

Key clinical trials

• A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Induction- PF-06480605 450 mg SC Q4W CI brief — competitive landscape report
• Induction- PF-06480605 450 mg SC Q4W updates RSS · CI watch RSS
• Pfizer portfolio CI

Frequently asked questions about Induction- PF-06480605 450 mg SC Q4W

Related

• Drug class: All small molecule drugs
• Target: All drugs targeting IL-17 receptor
• Manufacturer: Pfizer — full pipeline
• Therapeutic area: All drugs in Immunology
• Indication: Drugs for Moderate to severe plaque psoriasis
• Indication: Drugs for Active psoriatic arthritis
• Indication: Drugs for Active ankylosing spondylitis
• Compare: Induction- PF-06480605 450 mg SC Q4W vs similar drugs
• Pricing: Induction- PF-06480605 450 mg SC Q4W cost, discount & access